/, CXC chemokines/Mouse SDF-1 beta Recombinant

Mouse SDF-1 beta Recombinant

Categories:

$70.00$2,700.00

SKU: RKP402241 Tags: , , , , , ,

Description

Accession
P40224
Source
Optimized DNA sequence encoding Mouse Stromal Cell-Derived Factor-1 beta mature chain was expressed in Escherichia Coli.
Molecular weight
Native Mouse SDF-1 beta, generated by the proteolytic removal of the signal peptide and propeptide,the molecule has a calculated molecular mass of approximately kDa. Recombinant Mouse SDF-1 beta is a monomer protein consisting of73 amino acid residue subunits, migrates as an approximately kDa protein under non-reducing and reducing conditions in SDS-PAGE.
Purity
>97%, as determined by SDS-PAGE and HPLC
Biological Activity
Determined by its ability to chemoattract human peripheral T cells activated with PHA and IL-2 using a concentration range of-40 ng/ml.

Protein Sequence
MDAKVVAVLA LVLAALCISD GKPVSLSYRC PCRFFESHIA RANVKHLKIL NTPNCALQIV ARLKNNNRQV CIDPKLKWIQ EYLEKALNKR LKM
Endotoxin
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than.1 ng/µg(1EU/µg).
Presentation
Mouse SDF-1 beta was lyophilized from a.2 μm filtered solution in.5% glycine,.5% sucrose,.01% Tween80, mM Glutamic acid, pH.5.
Reconstitution
A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than.1 mg/mL. This solution can then be diluted into other buffers.
Storage
The lyophilized protein is stable for at least years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at° -° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Usage
This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.
Interactor
Q8JLJ0
Interactor
Q8QMN0
Interactor
Q9JFT2
Biological Process
Molecular function
Molecular function

Methods

Migration assay

  • Chemotaxis experiments were performed in polycarbonate transwell inserts (8 µm pore .).
  • SDF-1α was added in the lower chamber at the concentration of 100 ng/ml.
  • Cells were seeded at a density of 1.5×105 per well in the upper compartment and were cultured at 37°C for 14 h. Non-migrating Cells were removed from the upper surface by gentle scrubbing.
  • Migrating cells attached to the lower membrane stained with 0.1% crystal violet and were counted in five random fields.

SDF-1α Stimulations

  • Total thymocytes were resuspended at 1×107 cells/mL in DMEM with 0.1% BSA.
  • Cells were pre-treated or not with 20 µM of the PI3K inhibitor, LY294002, for 30 min at 37°C.
  • Cells were stimulated with 10 nM SDF-1α for various time points, immediately fixed in 1X Phosflow Lyse/Fix Buffer and washed once with FACS buffer.
  • Thymocytes were then permeabilized in 90% methanol on ice for a minimum of 30 min and washed twice in FACS buffer.
  • AKT activation was detected with anti-pAKT (1/100) followed by incubation with an Alexa fluor 647 conjugated anti-rabbit secondary Ab.
  • ERK activation was detected with anti-pERK (1/400) followed by incubation with biotin conjugated anti-mouse Ab and APC conjugated streptavidin.
  • Cells were also stained with Abs to surface markers and analyzed by flow cytometry.
  • ERK/AKT phosphorylation was quantified as fold induction of mean fluorescent intensities of stimulated samples/unstimulated samples.

Transwell Migration Assay

  • The bottom chambers of 24-well transwell plates (8 µm pore polycarbonate membrane transwell, ) contained 600 µl of each assaying condition in complete media (RPMI +10% FBS, for THP-1 cells) or minimal media (DMEM for RAW264.7 cells).
  • For THP-1 cells the bottom chambers of the transwells containing RPMI media were untreated or contained PKRA7 (1 µg/ml), MCP-1 (100 ng/ml), MCP-1+ PKRA7, PK2 (200 ng/ml), or PK2+ PKRA7 in triplicate per condition.
  • For RAW264.7 cells the bottom chambers of the transwells containing DMEM media were untreated or contained PKRA7 (1 µg/ml), SDF-1α (200 ng/ml), SDF-1α+PKRA7, (200 ng/ml), or + PKRA7 in triplicate per condition.
  • MCP-1, SDF-1α and PK2 all dissolved in water plus 0.1% BSA (water +0.1% BSA used as control).
  • The appropriate number of cells was collected in complete (THP-1) or minimal media (RAW264.7) and 100 µl were plated onto the…

Reduction of flotillin-1 and -2 expression in murine T-lymphoblasts impairs moesin capping and uropod formation.

  • Murine T-lymphoblasts prepared as in were untreated or treated with 10 nM SDF-1α for 15 min, and lysates were immunoblotted for total or P-ERM proteins.

SDF-1α is elevated in wound fluid and increases tumor growth.

  • A. SDF-1α levels in wound fluid from BALB/c wildtype mice were higher than in wound fluid from BALB/c nu/nu mice (nu/nu) or plasma from BALB/c WT animals (cytokine microarray).

Angiogenic potential of AGT+/− EPCs is decreased in vitro.

  • The migration assay was performed using EGM-2 basal media containing VEGF (10 ng/ml), EGF (50 ng/ml), or SDF-1α (100 ng/ml), which served as chemoattractants.

The level of SDF-1α is higher in serum and osteoblasts from Fgfr1 mice after LPS treatment.

  • Serum SDF-1α level was significantly higher in LPS treated Fgfr1 mice than Fgfr1mice.
Stay in the loop
For new product information and regular updates on our product range please fill your details
Loading